Results 1 to 10 of about 96,322 (259)

Long-Term Outcomes and Prognostic Factors in Metastatic <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center. [PDF]

Cancers (Basel)
Koçanoğlu A, Ünsal O, Kuş F, Gürçay N, Zeynelgil E, Düzköprü Y, Karakaya S.   +6 more
europepmc   +1 more source

Single-Site ALK-Positive Histiocytosis With TFG-ALK Fusion: Expanding the Clinical Spectrum of This Rare Entity. [PDF]

Am J Case Rep
Dasgupta M, Horvath D, Bevill B, Scheiderer A, Jordan S.   +4 more
europepmc   +1 more source

Monitoring EML4-ALK Biomarkers via a Microfluidic Assay for Treatment Efficacy Assessment. [PDF]

Biosensors (Basel)
Doron S, Brio L, Krasner M, Barbiro-Michaely E, Gerber D.   +4 more
europepmc   +1 more source

ALK+ Anaplastic Large Cell Lymphoma of Null Cell Phenotype with Leukemic Transformation and Leukemoid Reaction

Turkish Journal of Hematology, 2019
Shih-Sung Chuang, Yen-Chuan Hsieh, Hung-Chang Wu   +2 more
doaj   +1 more source

Advanced ALK-EML4 fusion-positive non-small cell lung cancer with intraspinal metastases: a case report. [PDF]

Front Oncol
Lang J, Guo B, Han Q, Xiong Z.
europepmc   +1 more source

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline. [PDF]

Drug Des Devel Ther
Guo Z, Zhang Y, Chen H, Dong X, Lei W, Zhong L, Yang J, Huang H, Chen Z, Liang W.   +9 more
europepmc   +1 more source

Virtual screening and MD simulation-guided discovery of CDK12-IN-3, a potent ALK inhibitor suppressing neuroblastoma growth <i>in vitro</i> and <i>in vivo</i>. [PDF]

Front Chem
Liu T, Hu X, Yan W, Yin H, Li Z.
europepmc   +1 more source

Lorlatinib-specific outcomes by timing of lorlatinib initiation in advanced ALK-positive non-small cell lung cancer: A retrospective cohort study. [PDF]

Ther Adv Med Oncol
Song R, Li X, Han N, Liu D, Xu Y.
europepmc   +1 more source

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance. [PDF]

Front Pharmacol
Cao M, Li S, Cao L, Tao F, Li N.
europepmc   +1 more source

Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare <i>WDR43::ALK</i> structural deletion. [PDF]

Front Oncol
Epler L, Velasquez G, Mambetsariev I, Arias-Romero J, Fricke J, Chen N, Babikian R, Ngo L, Arvanitis L, Kulkarni AA, Urgun DA, Gruber S, Afkhami M, Salgia R.   +13 more
europepmc   +1 more source